U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07556796) titled 'Study of IBI3016 in People With Mild or Moderate Hypertension Patients' on April 14.
Brief Summary: A Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and pharmacodynamic characteristics of a single subcutaneous dose of IBI3016 in Chinese patients with mild to moderate hypertension.
Study Start Date: May 15
Study Type: INTERVENTIONAL
Condition:
Hypertension
Intervention:
DRUG: IBI3016
Solution of Injection
OTHER: Placebo
0.9% sodium chloride saline solution
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Published by HT Digital Content Serv...